Dermapharm Holding SE Net Assets
Dermapharm Holding SE net assets. Based on the latest financial reports, Dermapharm Holding SE (DMP) has net assets worth €735.17 Million EUR (≈ $859.49 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.27 Billion ≈ $2.66 Billion USD) and total liabilities (€1.54 Billion ≈ $1.80 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore DMP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €735.17 Million |
| % of Total Assets | 32.35% |
| Annual Growth Rate | 26.61% |
| 5-Year Change | 40.41% |
| 10-Year Change | 1054.21% |
| Growth Volatility | 66.04 |
Net Assets of Dermapharm Holding SE (2013–2025)
Net assets of Dermapharm Holding SE from 2013 to 2025. This chart illustrates how Dermapharm Holding SE's net assets have evolved over time, based on quarterly financial data. See Dermapharm Holding SE (DMP) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Dermapharm Holding SE (2013–2025)
The table below shows the annual net assets of Dermapharm Holding SE from 2013 to 2025. For live market cap and overall valuation, see Dermapharm Holding SE stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €701.83 Million ≈ $820.51 Million |
+15.38% |
| 2024-12-31 | €608.29 Million ≈ $711.16 Million |
+11.60% |
| 2023-12-31 | €545.05 Million ≈ $637.22 Million |
+2.36% |
| 2022-12-31 | €532.49 Million ≈ $622.54 Million |
+6.53% |
| 2021-12-31 | €499.83 Million ≈ $584.36 Million |
+53.99% |
| 2020-12-31 | €324.58 Million ≈ $379.47 Million |
+14.09% |
| 2019-12-31 | €284.49 Million ≈ $332.60 Million |
+11.09% |
| 2018-12-31 | €256.08 Million ≈ $299.39 Million |
+247.54% |
| 2017-12-31 | €73.69 Million ≈ $86.15 Million |
+21.18% |
| 2016-12-31 | €60.81 Million ≈ $71.09 Million |
+36.82% |
| 2015-12-31 | €44.44 Million ≈ $51.96 Million |
+30.67% |
| 2014-12-31 | €34.01 Million ≈ $39.76 Million |
-17.77% |
| 2013-12-31 | €41.36 Million ≈ $48.36 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Dermapharm Holding SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1421.4% over the analyzed period, indicating profitable operations and earnings retention.
Dermapharm Holding SE Net Assets Breakdown (December 2025)
Dermapharm Holding SE net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €515.91 Million | 74.30% |
| Common Stock | €53.84 Million | 7.75% |
| Other Comprehensive Income | €23.83 Million | 3.43% |
| Other Components | €100.79 Million | 14.52% |
| Total Equity | €694.38 Million | 100.00% |
Dermapharm Holding SE Competitors by Market Cap
The table below lists competitors of Dermapharm Holding SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
$1.97 Billion |
|
CleanSpark Inc
NASDAQ:CLSK
|
$1.97 Billion |
|
North West Company Inc
TO:NWC
|
$1.97 Billion |
|
Aadhar Housing Finance Ltd
NSE:AADHARHFC
|
$1.97 Billion |
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
$1.97 Billion |
|
Mesoblast Ltd
NASDAQ:MESO
|
$1.97 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
$1.97 Billion |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
$1.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dermapharm Holding SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 604,422,000 to 694,376,000, a change of 89,954,000 (14.9%).
- Net income of 132,412,000 contributed positively to equity growth.
- Dividend payments of 48,456,000 reduced retained earnings.
- Other comprehensive income increased equity by 7,232,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €132.41 Million | +19.07% |
| Dividends Paid | €48.46 Million | -6.98% |
| Other Comprehensive Income | €7.23 Million | +1.04% |
| Other Changes | €-1.23 Million | -0.18% |
| Total Change | €- | 14.88% |
Book Value vs Market Value Analysis
This analysis compares Dermapharm Holding SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.99x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 73.40x to 2.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | €0.53 | €38.55 | x |
| 2015-12-31 | €0.76 | €38.55 | x |
| 2016-12-31 | €1.06 | €38.55 | x |
| 2017-12-31 | €1.37 | €38.55 | x |
| 2018-12-31 | €4.73 | €38.55 | x |
| 2019-12-31 | €5.18 | €38.55 | x |
| 2020-12-31 | €5.98 | €38.55 | x |
| 2021-12-31 | €9.24 | €38.55 | x |
| 2022-12-31 | €9.87 | €38.55 | x |
| 2023-12-31 | €10.01 | €38.55 | x |
| 2024-12-31 | €11.23 | €38.55 | x |
| 2025-12-31 | €12.90 | €38.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dermapharm Holding SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.37%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.18x
- Recent ROE (19.07%) is below the historical average (30.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -0.22% | -0.02% | 1.18x | 11.69x | €-2.89 Million |
| 2015 | 30.90% | 3.30% | 1.30x | 7.22x | €8.59 Million |
| 2016 | 29.56% | 3.79% | 1.43x | 5.48x | €11.13 Million |
| 2017 | 105.51% | 16.64% | 1.12x | 5.64x | €70.38 Million |
| 2018 | 29.84% | 13.16% | 0.81x | 2.79x | €50.08 Million |
| 2019 | 27.70% | 11.01% | 0.67x | 3.75x | €49.33 Million |
| 2020 | 26.66% | 10.81% | 0.65x | 3.80x | €53.63 Million |
| 2021 | 42.14% | 22.23% | 0.67x | 2.83x | €159.85 Million |
| 2022 | 25.25% | 13.10% | 0.73x | 2.66x | €81.08 Million |
| 2023 | 11.57% | 5.49% | 0.53x | 4.01x | €8.45 Million |
| 2024 | 18.83% | 9.64% | 0.57x | 3.44x | €53.34 Million |
| 2025 | 19.07% | 11.37% | 0.53x | 3.18x | €62.97 Million |
Industry Comparison
This section compares Dermapharm Holding SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,729,794,157
- Average return on equity (ROE) among peers: -99.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dermapharm Holding SE (DMP) | €735.17 Million | -0.22% | 2.09x | $1.97 Billion |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $56.62 Billion | 4.21% | 1.00x | $1.20 Billion |
| PEPTONIC MEDICAL (28L) | $47.09 Million | -78.27% | 0.82x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.05 Billion | 11.11% | 0.41x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $35.36 Billion | 15.71% | 0.13x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $60.94 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $20.26 Million | -37.64% | 0.19x | $6.62 Million |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more